Academic Journal
Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction.
| العنوان: | Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. |
|---|---|
| المؤلفون: | Fraz, Muhammad Asad, Warraich, Faiza Hassan, Warraich, Sami Ullah, Tariq, Muhammad Junaid, Warraich, Zabih, Khan, Ali Younas, Usman, Muhammad, Ijaz, Awais, Tenneti, Pavan, Mushtaq, Adeela, Akbar, Faisal, Shahid, Zaina, MD, Ali, Zeeshan, Fazeel, Hafiz Muhammad, Rodriguez, Cesar, Nasar, Aboo, McBride, Ali, Anwer, Faiz |
| المصدر: | Department of Medicine |
| بيانات النشر: | LVHN Scholarly Works |
| سنة النشر: | 2019 |
| المجموعة: | Lehigh Valley Health Network: LVHN Scholarly Works |
| مصطلحات موضوعية: | Age Factors, Aged, 80 and over, Antineoplastic Agents, Comorbidity, Frailty, Humans, Middle Aged, Multiple Myeloma, Multiple Organ Failure, Precision Medicine, Quality of Life, Stem Cell Transplantation, Department of Medicine, Department of Medicine Fellows and Residents, Fellows and Residents, Medicine and Health Sciences |
| الوصف: | Multiple Myeloma (MM) is primarily a disease of old age with a median age of sixty-nine years at diagnosis. The development of novel therapies for induction and use of autologous stem cell transplantation has resulted in improved clinical outcomes and better quality of life for MM patients. Elderly patients, comprising the majority of MM population, have a higher incidence of age-related comorbidities, frailty and organ dysfunction which complicates the coordination of treatment and limits the selection of therapies. Even in the era of multiple chemotherapeutic options, the clinical heterogeneity of the myeloma patients' demands personalized treatments which often require dose-adjustments or dose delays. The use of reduced-dose regimens and various comorbidity indices has improved clinical outcome and regimen tolerability in MM patients with renal, neurological and bone abnormalities. We focus on advancements in the treatment of multiple myeloma with the goal to guide clinicians towards patient-specific management. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| Relation: | https://scholarlyworks.lvhn.org/medicine/3404; https://pubmed.ncbi.nlm.nih.gov/31014512/ |
| الاتاحة: | https://scholarlyworks.lvhn.org/medicine/3404 https://pubmed.ncbi.nlm.nih.gov/31014512/ |
| رقم الانضمام: | edsbas.9422608E |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |